was used to treat patients with no-reflow of coronary arteries to observe the effect on blood flow and patient prognosis.
subjects And Methods
From December 2016 to December 2017, a total of 960 cases (180 cases of acute ST-segment elevation myocardial infarction, 580 cases of acute coronary syndrome, and 200 cases of stable angina pectoris) were treated by coronary intervention in our hospital. A total of 105 cases (50 cases of acute ST-segment elevation myocardial infarction, 52 cases of acute coronary syndrome, and 3 cases of stable angina pectoris) were classified as no-reflow. The incidence of no-reflow was 11.9% (27.8% acute ST-segment elevation myocardial infarction, 8.97% acute coronary syndrome, and 1.50% stable angina pectoris) [ . Inclusion criteria: TIMI had Grade 0-1 blood flow after balloon expansion or stent release during coronary interventional therapy, which represented a total of 100 cases [ Figure 4 ].
Exclusion criteria
Patients with cardiogenic shock or heart failure during coronary intervention (Killip level IV), which had a total of five cases. Randomized controlled trials were conducted on enrolled patients. A random number table method was used to divide the two groups: the treatment group (50 cases) treated by sodium nitroprusside combined with verapamil and the control group (50 cases) treated with only sodium nitroprusside. The treatment group consisted of 25 males and 25 females, aged 59-76 years, with an average age of 67.2 ± 5.14 years. TIMI grading after no-reflow included Grade 0 in 28 cases and Grade I in 22 cases. In the control group, there were 26 males and 24 females, aged 58-78 years, with an average age of 66.3 ± 7.14 years. After no reflow, TIMI grading was Grade 0 in 26 cases and Grade I in 24 cases. There was no statistically Before the operation, both groups were given 180-mg ticagrelor and 300-mg aspirin orally. When no-reflow occurred during coronary intervention, the patients in the treatment group were promptly injected with 200-µg sodium nitroprusside and 200-µg verapamil into the distal segment of coronary arteries through a microcatheter. The control group was injected with 200-µg sodium nitroprusside in the same time frame and location. Coronary angiography was performed 2 min after the injection, and TIMI blood flow was closely monitored. Both groups received continuous intravenous pumping of 0.15μg/kg/min tirofiban for 24 h after the operation.
Observational indexes
(1) TIMI blood flow grading was compared between the two groups after medication. Grade 0: no blood flow filling and no blood flow in the distal segment of occluded vessels; Grade I: partial passing of the contrast agent, but no full filling in the distal segment of stenosis; Grade II: full filling in the distal segment of stenosis, but with slow development and slow elimination of the contrast agent; and Grade III: full filling in the distal segment of stenosis, as well as rapid filling and elimination of the contrast agent.
(2) The adverse cardiovascular events, such as angina pectoris, myocardial infarction, and left heart failure, were compared at follow-ups in the 6-month period following the operation.
Results

Thrombolysis test in myocardial infarction classification of two groups after medication
After using sodium nitroprusside and verapamil in the treatment group, there were 0 case (0.00%) of TIMI 0, 0 case (0.00%) of TIMI I, 10 cases (20.0%) of TIMI II, and 40 cases (80.0%) of TIMI III. In addition, after the application of sodium nitroprusside in the control group, there were 0 case (0.00%) of TIMI 0, 1 case (2.00%) of TIMI I, 22 cases (44.0%) of TIMI II, and 28 cases (56.0%) of TIMI III. There were statistically significantly more patients classified as TIMI III in the treatment group than in the control group (80.0 vs. 56.0, P < 0.05) [ Table 1 ].
Comparison of incidence of cardiovascular adverse events between the two groups
There were three follow-ups, including 1 month, 3 months, and 6 months after the operation. The follow-up rate was 100% and appointments consisted of measuring clinical symptoms, signs, routine blood lipid and glucose, liver and kidney function, electrocardiogram, cardiac color Doppler ultrasound, etc. There were two cases of angina pectoris, one case of myocardial infarction, and 0 case of left heart failure in the treatment group. There were five cases of angina pectoris, two cases of myocardial infarction, and two cases of left heart failure in the control group. The incidence of adverse events in the treatment group (three cases) was statistically significantly lower than that in the control group (nine cases; 6.00% vs. 18.0%, P < 0.05) [ Table 2 ].
discussion
There are numerous risk factors for no-reflow of coronary arteries. For instance, it is clinically believed that thrombotic lesions, emergency PCI treatment, prior myocardial infarction, and coronary artery bypass grafting have predictive significance for no-reflow, [3, 4] whereas coronary artery lesions such as ulcers, thrombosis, calcification, and lesions of saphenous vein graft may indicate higher risk of no-reflow. Furthermore, during coronary intervention, operations such as multiple balloon dilatation, posterior dilatation of high-pressure balloon, prolonged length of implanted stent, and rotational atherectomy can also promote the precipitation of atherosclerotic plaque debris, thereby leading to no-reflow. Therefore, in clinical practice, more attention should be paid to the standardized operation during surgeries for high-risk patients who are prone to develop no-reflow vascular lesion.
With the occurrence of no-reflow, especially when the flow in coronary artery is only TIMI 0-I Grade, the injected drugs through guided catheters may not be effective for their failure to reach the coronary microcirculation due to lack of blood flow usually. In order to solve this issue, sodium nitroprusside, verapamil, nitroglycerin, tirofiban, and other drugs can be injected to the distal end of related arteries by microcatheters or thrombus aspiration catheters to promote rapid release of drug effect generally. [5, 6] Verapamil, a calcium antagonist, can be applied to effectively reverse coronary microvascular spasm, inhibit calcium overload, reduce oxygen-free radical generation, protect heart muscle, and improve microcirculation function to relieve no-reflow. Verapamil can be applied intermittently and repeatedly with 100-200 µg per application. It is reported that no-reflow of coronary arteries can be remarkably improved by verapamil at the maximum dose of 1 mg. Occasionally, this results in heart rate drop or transient atrioventricular block, and physicians of patients with pump failure should pay attention to the negative inotropic activity of these drugs. Other calcium antagonists such as diltiazem and nicardipine can also exert such similar effects. Sodium nitroprusside is a nitric oxide donor, which has powerful vasodilating effect and can improve vascular endothelial function. In this article, TIMI flow was improved by applying sodium nitroprusside combined with verapamil when compared with that using sodium nitroprusside alone, and the incidence of adverse cardiovascular events was also lower in the period of follow-up after surgery. [7, 8] Results of this study indicate that sodium nitroprusside combined with verapamil is a more effective treatment for no-reflow of coronary arteries than sodium nitroprusside alone. However, for the limited samples in this study, there may be certain bias between the research results and the real cases. In addition, enrolled patients were only followed up intraoperatively and for 6 months postoperatively in this study, without a long-term follow-up. The long-term effect of the studied drugs requires further follow-ups in future.
conclusions Sodium nitroprusside combined with verapamil can significantly improve the no-reflow following coronary interventional therapy and reduce the incidence of adverse cardiovascular events.
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